Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Fineline Cube Apr 21, 2026
Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

Hengrui Launches Pediatric Trial of Dual GIPR/GLP-1R Agonist HRS9531 in Overweight and Obese Adolescents Following NMPA Clearance

Fineline Cube Apr 21, 2026
Company Drug

Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab

Fineline Cube Apr 21, 2026
Policy / Regulatory

NHSA Report: China’s Medical Insurance Fund Records Significant Growth and Savings in 2023

Fineline Cube Jul 26, 2024

The National Healthcare Security Administration (NHSA) has released its comprehensive annual statistical report for the...

Company Deals R&D

CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine

Fineline Cube Jul 26, 2024

CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic...

Company Deals

Shanghai’s Spectrum Dynamics Medical Secures Major Financing for Molecular Imaging Innovations

Fineline Cube Jul 26, 2024

Spectrum Dynamics Medical, a Shanghai-based specialist in medical molecular imaging, has reportedly secured hundreds of...

Company Deals

Shanghai GenTech Expands into Life Sciences with Acquisition of Konosai Biotechnology

Fineline Cube Jul 26, 2024

Shanghai GenTech Co., Ltd., a Chinese solutions provider with expertise in flat panel display, LED,...

Company Deals

Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development

Fineline Cube Jul 26, 2024

Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered...

Company Deals

United Imaging Healthcare Invests RMB 120 Million in Particle Accelerator Specialist Long Beam Technology

Fineline Cube Jul 26, 2024

United Imaging Healthcare (UIH, SHA: 688271), a leading medical device company in China, has announced...

Company Drug

Sinqi Pharmaceutical Gets NMPA Green Light for SQ-22031 Eye Drops to Treat Dry Eye Syndrome and Neurotrophic Keratitis

Fineline Cube Jul 26, 2024

Shenyang Sinqi Pharmaceutical Co., Ltd (SHE: 300573), a pharmaceutical company based in China, has received...

Company Medical Device

Lepu Scientech Secures NMPA Approval for RF Lance, Advancing Atrial Septal Puncture Technology

Fineline Cube Jul 26, 2024

Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading medical technology company based...

Company Medical Device

Amoy Diagnostics’ APACE Receives Japanese Approval as Companion Diagnostic for MET-Inhibiting Therapies

Fineline Cube Jul 26, 2024

Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a Chinese diagnostics company, has announced that it...

Company Drug

China’s NMPA Gives Tacit Nod to IASO Biotechnology’s IASO-782 for SLE Clinical Trials

Fineline Cube Jul 26, 2024

IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that the National Medical Products...

Company Drug

Luye Pharma’s Subsidiary Gets NMPA Go-Ahead for First CD228-Targeted ADC BA1302

Fineline Cube Jul 26, 2024

Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a subsidiary of China-based Luye Pharma Group (HKG:...

Company

AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges

Fineline Cube Jul 26, 2024

AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024,...

Company

Roche’s H1’24 Financials Show 5% Growth, Eye Care and Cancer Therapies Drive Sales

Fineline Cube Jul 26, 2024

Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO), the Swiss pharmaceutical and diagnostics giant, has reported...

Company

AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines

Fineline Cube Jul 26, 2024

AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second...

Company Deals Drug

Amoytop Biotech Opts for NASH Drug Candidate KN069 in Licensing Deal with Alphamab Oncology

Fineline Cube Jul 26, 2024

Xiamen Amoytop Biotech Co., Ltd (SHA: 688278), a biopharmaceutical company based in China, has exercised...

Company Deals

Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China

Fineline Cube Jul 25, 2024

Taiwan’s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal...

Company

Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions

Fineline Cube Jul 25, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results...

Company Deals

Agilent Technologies and Shanghai Majorbio Bio-pharm Ink Deal to Transform Life Science Research in China

Fineline Cube Jul 25, 2024

Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets,...

Company Deals

Nanjing Sanhome Pharmaceutical and China Resource Pharma Deepen Collaboration for Market Expansion

Fineline Cube Jul 25, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, and China Resource Pharmaceutical Commercial Group...

Company Drug

Jiangsu Suzhong Pharma’s Sutetinib Earns Breakthrough Designation for NSCLC from China’s NMPA

Fineline Cube Jul 25, 2024

Jiangsu Suzhong Pharma Group Co., Ltd, a leading pharmaceutical company based in China, has received...

Posts pagination

1 … 312 313 314 … 654

Recent updates

  • UPC Appeal Court Reverses Lower Ruling, Imposes Preliminary Injunction on Sinocare’s iCanCGM App in 17 European Countries Following Abbott Patent Claim
  • Hengrui Launches Pediatric Trial of Dual GIPR/GLP-1R Agonist HRS9531 in Overweight and Obese Adolescents Following NMPA Clearance
  • Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab
  • Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma
  • Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP Medical Device

UPC Appeal Court Reverses Lower Ruling, Imposes Preliminary Injunction on Sinocare’s iCanCGM App in 17 European Countries Following Abbott Patent Claim

Company Drug

Hengrui Launches Pediatric Trial of Dual GIPR/GLP-1R Agonist HRS9531 in Overweight and Obese Adolescents Following NMPA Clearance

Company Drug

Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.